Collaborations & Alliances

Nimbus Therapeutics, Lilly Enter Alliance for Therapeutics for Metabolic Diseases

Aim to develop targeted therapies designed to activate a specific isoform of AMPK to improve glucose and lipid homeostas while mitigating safety concerns.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Nimbus Therapeutics has entered a collaboration and licensing agreement with Eli Lilly for potential therapeutics for metabolic diseases with a potential value of $496 million.   The two companies will collaborate on the development of novel targeted therapies designed to activate a specific isoform of AMPK for the potential treatment of metabolic diseases. AMPK (AMP-activated protein kinase) is considered a high-value target in this indication due to its role in glucose, lipid metabolis...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters